WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST Invests $6.52 Million in Medline $MDLN

WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST purchased a new position in shares of Medline (NASDAQ:MDLN) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 146,602 shares of the company’s stock, valued at approximately $6,524,000. Medline accounts for approximately 0.1% of WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST’s investment portfolio, making the stock its 20th biggest holding.

Several other large investors have also recently added to or reduced their stakes in the stock. Mass General Brigham Inc purchased a new position in shares of Medline during the 4th quarter valued at $1,104,000. Baillie Gifford & Co. purchased a new stake in shares of Medline during the fourth quarter worth $437,236,000. Massachusetts Financial Services Co. MA acquired a new stake in Medline during the fourth quarter valued at $429,544,000. UBS Group AG purchased a new position in Medline in the fourth quarter valued at about $54,707,000. Finally, Pictet Asset Management Holding SA purchased a new position in Medline in the fourth quarter valued at about $48,996,000.

Insider Buying and Selling

In other news, insider Jessi L. Corcoran bought 5,000 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were acquired at an average cost of $34.15 per share, for a total transaction of $170,750.00. Following the purchase, the insider owned 5,000 shares of the company’s stock, valued at $170,750. This represents a ? increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Douglas P. Golwas sold 100,000 shares of Medline stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $36.77, for a total transaction of $3,677,000.00. Following the completion of the transaction, the insider owned 23,899 shares in the company, valued at $878,766.23. This trade represents a 80.71% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.81% of the company’s stock.

Medline Stock Performance

MDLN opened at $38.87 on Friday. The company has a market cap of $51.06 billion and a P/E ratio of 121.47. The business’s 50-day moving average is $38.99. Medline has a 52-week low of $32.81 and a 52-week high of $50.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.51 and a current ratio of 4.41.

Medline (NASDAQ:MDLN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.33 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.04. The company had revenue of $7.35 billion during the quarter. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. On average, research analysts predict that Medline will post 1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft set a $42.00 price target on Medline in a research note on Thursday, May 7th. JPMorgan Chase & Co. boosted their price target on Medline from $50.00 to $53.00 and gave the company an “overweight” rating in a research note on Tuesday, March 10th. BTIG Research reaffirmed a “buy” rating and set a $55.00 price objective on shares of Medline in a research report on Thursday, May 7th. Barclays reduced their target price on shares of Medline from $50.00 to $45.00 and set an “overweight” rating for the company in a research note on Monday, June 1st. Finally, BNP Paribas Exane decreased their target price on shares of Medline from $49.00 to $40.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $50.54.

Medline Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply?chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.